For example, in urologic cancer, common genes regulated by prognosis-alternative miRNAs such as BCL2, EGFR, KIT, PDGFRA, and VEGFA, have been validated as anti-cancer drug targets previously. This evidence concerns the gene BCL2 and cancer.